We are proud to be part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, taking place May 20–23, 2025, in Paris, France. Autonomix’s technology and early proof-of-concept study results will be featured in a poster presentation. Learn more: https://bit.ly/4lL4Z5C #EuroPCR
Autonomix Medical
Biotechnology Research
The Woodlands, TX 1,922 followers
Breakthrough Technology For The Peripheral Nervous System
About us
Autonomix (Nasdaq: AMIX) is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.
- Website
-
https://autonomix.com/
External link for Autonomix Medical
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- The Woodlands, TX
- Type
- Privately Held
- Specialties
- Peripheral Nervous System, Breakthrough Technology, Nerve Signaling, and Precision-Guided Therapy
Locations
-
Primary
Get directions
The Woodlands, TX 77380, US
Employees at Autonomix Medical
-
Wally Klemp
Biotech Executive
-
Jennifer Cook
Chief Business Officer at Autononix Medical (NASDAQ: AMIX)
-
Julie Manchester
Regulatory & Quality Leader | OCRA-DG Board Member | Biotech/Med Device | RAC | CQM/OE |
-
Shaun Pratt
Director of Corporate Accounting and Reporting at Autonomix Medical, Inc.
Updates
-
Our CEO, Brad Hauser, comments on the Company's recently granted European patent which underscores the breadth of application and expansion opportunities for Autonomix's catheter-based technology. Learn more: https://bit.ly/4itFHXa
-
Autonomix has recently been granted a patent titled, “Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development” by the European Patent Office, growing Autonomix's global patent portfolio to over 80 issued patents and 40 pending patent applications. Read more: https://bit.ly/4itFHXa
-
Autonomix today announced that the European Patent Office (EPO) has granted Patent No. 3,226,792 (the ‘792) titled, “Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development.” The granted ‘792 patent relates to the field of neuromodulation and covers a range of methods and systems used in nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures related to the systems and mechanisms that regulate prostate and tumor growth. For details: https://bit.ly/4itFHXa
-
Stay up-to-date with the future of Autonomix. Sign up for email alerts to receive the latest updates: https://bit.ly/3UTPr3d #AMIX #PancreaticCancer #Electrophysiology #MedTech
-
#PatientSpotlight: Listen to the firsthand experiences from the treating physician and patients who took part in our first-in-human clinical trial addressing #PancreaticCancer #Pain here: https://bit.ly/3MiiUzJ #AMIX #MedTech #PainManagement #Electrophysiology
-
Find details of Autonomix's upcoming poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13th - April 16th in Rotterdam, Netherlands on our website: https://bit.ly/4iW5ok6 #ECIO2025
-
Our CEO Brad Hauser comments on the Company's recent engagement of leading medical experts to support Autonomix's U.S. clinical and regulatory pathway towards a De Novo application for FDA approval: https://bit.ly/3FZDLYM
-
Discover the Power of Autonomix’s Nerve Sensing Catheter Technology. #AMIX #PancreaticCancer #Electrophysiology #MedTech
-
Autonomix is on track to commence clinical studies in the U.S. in 2025 to support a De Novo application for FDA approval. Learn more about our progress and the leading U.S. and international-based medical experts guiding our clinical and regulatory path: https://bit.ly/3FZDLYM